Trastuzumab Emtansine (Kadcyla) - 21 days. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Trastuzumab Emtansine (Kadcyla) - 21 days, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6547/206_v4_Trastuzumab_Emtansine_21days.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (i) Received prior therapy for locally advanced or metastatic disease, or (ii) Developed disease recurrence during or within six months of completing adjuvant therapy.	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
HSE (1)	HER2-positive	Invasive Breast Carcinoma	Trastuzumab emtansine